Fund Focused on Biomedical Companies in China -- BioVeda Capital, a Singapore-based venture capital firm, announced that Lilly Asia Ventures has made a $10 million investment into the BioVeda China fund. BioVeda China is the first international venture capital fund dedicated to making life science investments in China.BioVeda China will seek to identify companies that can become future industry leaders, transforming them into next-generation multinationals. More details...